Moodbeam is delighted to announce the appointment of a non-executive Medical and Scientific director to the board in the form of Dr. Bruce Charlesworth.

Bruce is a qualified doctor who subsequent to practicing medicine in the NHS has held a variety of positions in global healthcare businesses over the past 20 years. 

He has been responsible for the development and launch of a number of pharmaceutical and diagnostic products as well as the success of a global health outcomes research agency, Adelphi Values. 

He brings clinical understanding, a passion for making science do good in the world and significant product development know-how that will help the work we do at Moodbeamgo from strength to strength.

Dr. Charlesworth is currently a vice president of Healthcare Research and Development at RB, a leading health and consumer goods company, famous for household brands such as Dettol, Durex, Nurofen and Gaviscon. Bruce leads the R&D teams on the 1400 strong Hull site.

Needless to say, the entire team at Moodbeam are delighted with Bruce’s appointment. Here is Jonathan Elvidge, co-founder and co-director of Moodbeam, with his thoughts on the appointment:

“Bringing Bruce on board is a real milestone for Moodbeam. To have this level of expertise and support from someone with such a relevant and successfully executed skillset, can only enrich the team, its direction and the integrity of Moodbeam, and its intention to change lives for the better”.